AbbVie and Boehringer Ingelheim entered a global immunology collaboration. AbbVie paid $595M upfront plus up to $1.6B in milestones for license to BI 655066 (risankizumab), an anti-IL-23 antibody in Phase 3 for psoriasis, plus rights to anti-CD40 antibody BI 655064. AbbVie became sole commercialization lead, with BI retaining co-promote option in asthma. Risankizumab approved as Skyrizi in 2019.